IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q4 2023 Earnings Call Transcript

We’re not guiding regionally, but the 5%, we’re expecting solid net price realization globally consistent with what we’re able to execute this year. And so I think we’re, again, without being specific, you should expect solid price realization in US and international regions. And days, we don’t have a material kind of full year dynamic. We’ll share clarity as we go through quarter-by-quarter on that, but we’re not highlighting that as an issue in Q1 and it’s — or for the full year.

Jonathan Block: All right. Thanks, guys.

Jay Mazelsky: Okay. Thank you. So we don’t have further questions. So with that, thank you for your questions. We’ll now conclude our Q&A portion of this morning’s call. It’s been a pleasure to review another quarter of strong IDEXX results. In summary, IDEXX is well positioned to sustain the momentum we’ve built into 2024, which will continue to help us address the significant decades-long opportunity to raise the standard of care for companion animal health care. Our consistent strategy focused on supporting increased utilization of diagnostics is a key factor in elevating the standards of care and has helped us navigate the highly dynamic external environment in our sector. We look forward to continued strong execution against our strategic priorities by teams across IDEXX as we move forward through 2024 and beyond. So thank you for your participation this morning, and we’ll now conclude the call.

Operator: This concludes today’s call. Thank you for your participation. You may now disconnect.